Global End Stage Renal Disease Market
Global End Stage Renal Disease (ESRD) Market By Segmentation | End Stage Renal Disease Industry Volume, Value, Trends, Size, Share, Sales, and Key Players Revenue Analysis Report 2021-2026
Published: September 2020 | Report ID:DRR12 | Pages: 150
End Stage Renal Disease Market Size, Growth and Forecast (2021-2026):
The Global End Stage Renal Disease Market value is estimated at USD 70 billion in 2021 and is projected to reach USD 172 billion by 2026 at a CAGR of 12% during the forecast period 2021-2026.
End Stage Renal Disease Market is segmented by Treatment into Transplantation, Dialysis, By End User into Hospital, Clinic, Others.
Growth in Asia Pacific Region:
According to our research analysis done by the Data Research Reports, Asia Pacific region is anticipated to grow at a highest CAGR of during the assessment year (2021-2026) due to growth in the aging population, increasing patient affordability and various lifestyle stress.
End Stage Renal Disease Market Geographical Analysis:
- North America
- United States
- Canada
- Rest of North America
- Europe
- United Kingdom
- Spain
- Germany
- Italy
- France
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia
- Singapore
- Malaysia
- South Korea
- New Zealand
- Rest of APAC
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of LATAM
- Middle East and Africa
- Middle East
- Africa
End Stage Renal Disease Market Segmentation Analysis:
By Treatment:
- Transplantation
- Dialysis
By End User:
- Hospital
- Clinic
- Others
Key Players in the Market:
Major key Players in the Global End Stage Renal Disease Market are
- Medtronic
- Fresenius Medical Care Ag & Co. Kgaa
- Braun Melsungen Ag
- Baxter International, Inc.
- Asahi Kasei Medical Co., Ltd.
- Cantel Medical
- Bd
- Nikkiso Co., Ltd
- Jms Co. Ltd
- Preface
1.1 Market Definition and Scope
1.2 Base Currency, Base Year and Forecast Periods
1.3 Key Research Objectives
1.4 Research Highlights
- General Study Assumptions
- Research Methodology
3.1 Introduction
3.2 Secondary Research
3.3 Primary Research
3.4 Analysis Design
3.5 Study Timeline
- Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Market Trends
- Supply Chain Analysis
- Company Strategy Analysis
6.1 Merger and Acquisition Analysis
6.2 Agreements, Collaborations and Joint Ventures
6.3 Regional Presence
6.4 New Product Launches
- Market Outlook
7.1 Technological Advancement
7.2 Pricing Analysis
7.3 Epidemiology
7.4 Product Landscape Analysis (Brand Tracking Analysis & Pipeline Analysis)
- Market Segmentation
8.1 Overview
8.2 End Stage Renal Disease Market, By Treatment, forecast year 2021-2026
8.2.1 Transplantation
8.2.2 Dialysis
8.2.3 Market Size Estimations & Forecasts (2021-2026)
8.3.4 Y-o-Y Growth Analysis
8.3.5 Market Investment Opportunities Analysis
8.3 End Stage Renal Disease Market, By End User, forecast year 2021-2026
8.3.1 Hospital
8.3.2 Clinic
8.3.2 Others
8.3.3 Market Size Estimations & Forecasts (2021-2026)
8.3.4 Y-o-Y Growth Analysis
8.3.5 Market Investment Opportunities Analysis
- Global Market Regional and Country Analysis, Forecast 2021-2026
9.1 Overview
9.2 Regional Trends
9.3 Impact Analysis
9.4 Key Findings
9.5 End Stage Renal Disease Market, by Region, 2021-2026
9.5.1 By Treatment
9.5.2 By End User
- Competitive Landscape Analysis
10.1 Market Player
10.1.1 Company Revenue
10.1.2 Business unit
10.1.3 Product Mapping
10.1.4 Geographical Locations
10.2 Company Share Analysis
- Strategic Analysis
11.1 PESTLE analysis
11.2 Porter’s Five analysis
11.2.1 Bargaining Power of Suppliers
11.2.2 Bargaining Power of Consumers
11.2.3 Threat of New Entrants
11.2.4 Threat of Substitute Products and Services
11.2.5 Competitive Rivalry within the Industry
- Company Profiles
12.1 Medtronic
12.1.1 Overview
12.1.2 Product Portfolio
12.1.3 Financial Details
12.1.4 SWOT Analysis
12.1.5 Market Strategies
12.2 Fresenius Medical Care Ag & Co. Kgaa
12.3 B. Braun Melsungen Ag
12.4 Baxter International, Inc
12.5 Asahi Kasei Medical Co., Ltd
12.6 Cantel Medical
12.7 Bd
12.8 Nikkiso Co., Ltd
12.9 Jms Co. Ltd
- Market Guidance
- Appendix